GSK PLC closed 26.98% short of its 52-week high of £18.24, which the company reached on May 16th.

At first, drug companies seemed to agree. For example, in 2018, 23andMe granted pharmaceutical company GlaxoSmithKline an ...

Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...

A study of over 280,000 adults found that the shingles vaccine reduced dementia risk by 20%, with a stronger effect in women.

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...

Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays ...

Learn more about whether Corcept Therapeutics Incorporated or GSK plc is a better investment based on AAII's A+ Investor ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

outreach and access These grants are part of GSK’s COiMMUNITY Initiative, which aims to address adult immunization barriers through funding, increased data transparency and resource-sharing ...

ABL Bio Inc. sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier penetrating bispecific antibody platform, ...

NEW YORK CITY, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

GSK PLC closed 21.39% short of its 52-week high of £18.24, which the company reached on May 16th.